Literature DB >> 31343323

One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis.

Camille V Edwards1, Divaya Bhutani2, Markus Mapara2, Jai Radhakrishnan3, Sofia Shames4, Mathew S Maurer4, Siyang Leng2, Jonathan S Wall5, Alan Solomon5, Andrew Eisenberger2, Suzanne Lentzsch2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31343323     DOI： 10.1080/13506129.2019.1584892

Source DB:  PubMed          Journal:  Amyloid        ISSN： 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  10 in total

Review 1.  Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.

Authors:  Hidehiko Ikura; Jin Endo; Hiroki Kitakata; Hidenori Moriyama; Motoaki Sano; Keiichi Fukuda
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

2.  Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design.

Authors:  Nicholas L Yan; Diogo Santos-Martins; Reji Nair; Alan Chu; Ian A Wilson; Kristen A Johnson; Stefano Forli; Gareth J Morgan; H Michael Petrassi; Jeffery W Kelly
Journal:  J Med Chem       Date:  2021-05-03       Impact factor: 7.446

Review 3.  Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

Authors:  Jan M Griffin; Hannah Rosenblum; Mathew S Maurer
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 4.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

Review 5.  AL amyloidosis: advances in diagnosis and management.

Authors:  Youngil Koh
Journal:  Blood Res       Date:  2020-07-31

Review 6.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

7.  Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Authors:  Vikram J Premkumar; Suzanne Lentzsch; Samuel Pan; Divaya Bhutani; Joshua Richter; Sundar Jagannath; Michaela Liedtke; Arnaud Jaccard; Ashutosh D Wechalekar; Raymond Comenzo; Vaishali Sanchorawala; Bruno Royer; Michael Rosenzweig; Jason Valent; Stefan Schönland; Rafael Fonseca; Sandy Wong; Prashant Kapoor
Journal:  Blood Cancer J       Date:  2021-01-11       Impact factor: 11.037

Review 8.  AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Giada Bianchi; Yifei Zhang; Raymond L Comenzo
Journal:  JACC CardioOncol       Date:  2021-10-19

Review 9.  Future Perspectives.

Authors:  Angela Dispenzieri; Giampaolo Merlini
Journal:  Hematol Oncol Clin North Am       Date:  2020-12       Impact factor: 3.722

10.  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Lawreen H Connors; Lisa M Mendelson; Tracy Joshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-08-04       Impact factor: 11.037
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.